GLP-1 drugs, formally called glucagon-like peptide-1 receptor agonists, are incretin-based therapies that activate the GLP-1 receptor
Ricci AG, Olivares CN, Bilotas MA, Baston JI, Singla JJ, Meresman GF, et al
Cell Cycle 12 , 35643573 (2013)
Andreani T, Cheng R, Elbadri K, Ferro C, Menezes T, dos Santos MR, Pereira CM, Santos HA
Key approved indications include: Type 2 diabetes mellitus management (Mounjaro) Chronic weight management in obesity or overweight with comorbidities (Zepbound) Use as adjunct to lifestyle modification (diet and exercise) It is critical to recognize that tirzepatide has no FDA approval for the treatment, prevention, or management of autoimmune diseases
Oral: Some individuals experience transient gastric discomfort with oral bpc 157